Inhibrx shares HNSCC response data for OX40 agonist reportedly on the takeout table

🌐 FirstWord Pharma —
Inhibrx shares HNSCC response data for OX40 agonist reportedly on the takeout table

AI Summary

Inhibrx has presented data indicating the efficacy of its OX40 agonist in treating HNSCC, raising speculation about potential acquisition interest. The findings could influence market positioning within the oncology sector.

Markets Deals Health Inhibrx HNSCC OX40 agonist oncology acquisition clinical data

Read original source →